Paper Details

  1. Home
  2. Paper Details

Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.

Author: EndoJunki, FukudaYoshihisa, HayashiHideki, HiroseChiemi, IiharaHirotoshi, KaitoDaizo, KitahoraMika, OhnoYasushi, SugiyamaTadashi, SuzukiAkio, YanaseKomei

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Afatinib, an EGFR-TKI, is effective in treating lung cancer but can cause severe diarrhea and skin disorders, impacting quality of life and leading to treatment interruption. This study aims to understand the association between individual variations, pharmacokinetics, and genetic polymorphisms to predict the occurrence of these side effects.
Paper Details　
Original Abstract of the Article :
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) represent the first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Afatinib is a second-generation EGFR-TKI with excellent therapeutic effects. However, severe diarrhea and skin diso...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2019.05.013

データ提供：米国国立医学図書館（NLM）

Affinib: A Powerful EGFR-TKI, But with Side Effects

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Affinib, a second-generation EGFR-TKI, has proven to be highly effective in treating EGFR mutation-positive NSCLC. However, this powerful drug can also cause significant side effects, particularly severe diarrhea and skin disorders, which can lead to treatment interruptions and compromise quality of life. This study investigates the relationship between genetic polymorphisms and the occurrence of these side effects.

Unraveling the Genetics of Side Effects: A Personalized Approach to EGFR-TKI Treatment

The study explores the association between genetic variations, pharmacokinetics, and the development of side effects from affinib. The researchers sought to understand how individual differences in genetic makeup could influence the body's response to this potent drug. This study is like searching for a hidden oasis in the desert of genomic medicine, aiming to personalize EGFR-TKI treatment and minimize the impact of side effects.

A Personalized Approach to Treatment: Optimizing Therapy for NSCLC Patients

Understanding the genetic basis of side effects can lead to more personalized treatment strategies for NSCLC patients. This could involve adjusting dosage, monitoring for potential adverse events, or even choosing alternative treatments based on individual genetic profiles. By deciphering the genetic code underlying these side effects, we can navigate the desert of NSCLC treatment more effectively, improving patient care and outcomes.

Dr.Camel's Conclusion

This study is a journey into the desert of genetic variations, seeking to understand how individual differences influence the side effects of affinib, a powerful EGFR-TKI used to treat NSCLC. By unmasking the genetic factors behind these side effects, we can optimize treatment strategies for NSCLC patients, providing more personalized and effective care. This research is like discovering a hidden oasis in the desert of genomic medicine, offering a chance to tailor therapy and improve the lives of patients battling this challenging disease.

Date :
  1. Date Completed 2020-06-22
  2. Date Revised 2020-06-22
Further Info :

Pubmed ID

31319966

DOI: Digital Object Identifier

10.1016/j.lungcan.2019.05.013

Related Literature

Article Analysis
・Side Effects of afatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.